"Raymond, Larry"<EMAIL_ADDRESS>11/02/2005 05:51 PM	To
Margaret Sheppard/DC/USEPA/US@EPA
cc

bcc

Subject
RE: Costs of treating 1-BP impairment

	History:
This message has been replied to and forwarded.

Nice to hear from you, Margaret. I fear that our small sample and
follow-up on only 2 of our initial four workers are substantial
limitations, but I'll plunge ahead anyway. Our Case 2 was re-exposed
twice at the first employer and then at another employer about 20 miles
away from the first one. She was hospitalized three times at what I
estimate as $20,000 each time (special CT and MRI imaging, spinal fluid
examination, consultations by brain, kidney and other specialists)
followed by rehabilitation for another $2,000, twice. She then underwent
vocational rehabilitation, which prepared her to attend community
college, after which she will be a Medical Office Assistant. She wants
to become certified as a Phlebotomist, and could later attend Nursing
School. Since her claims for medical expenses and lost wages was
initially denied, she had to retain legal counsel, and was awarded a
financial settlement, but I do not have those details. Happily, the
child who was conceived during her initial 1-BP illness was born healthy
and is now in First Grade, apparently doing fine. She had a spontaneous
miscarriage about 2 years later, and has not been pregnant since. Time
away from work likely added up to a year or more.

Case 1 left the furniture business, and was able to obtain a sedentary
job at which I believe she is still working. She, too, was hospitalized
twice and had expenses similar to those above.

Cases 3 and 4 were lost to our follow-up, soon after their (single)
hospitaliztion and referral from the Piedmont Triad area to our
Charlotte medical center. Neuropsychological evaluations of Case 3 added
another $2,000 to the cost of his care. I do not have information on the
rehabilitation costs which these two patients may have generated.

The treatment of 1-BP intoxication is pretty simple, once the diagnosis
is suspected. Brisk intravenous salt-and-water ("normal saline") therapy
and a strong diuretic (furosemide/Lasix)  helps the kidney eliminate the
bromide ions. However, the attempts to do this treatment by oral
hydration didn't work in the patients we later observed, because they
could not tolerate the volumes of saline needed to wash out the 1-BP.
Hence, the hospitalizations.

Lingering pain and abnormal sensations (dysesthesias) may require the
use of special medicines which to control neurologic symptoms, and the
expense of these (e.g., gabapentin) could run to $200/month (my
estimate, I haven't check with Pharmacies)and might be indefinite. The
most grievous symptom (ataxia, unsteadiness of gait) has no treatment,
and runs the risk of falling with possible fractures or head injuries,
but neither of these occurred in our 4 patients.

As you may recall from the Orlando workshop, Margaret, permanent
neurological impairments were the result of 1-BP intoxication. As Case 2
recently put the matter, "It is a drastic, life-changing event and it
makes a person value the things we all take for granted in life."

I wish I were smart enough to dissect out which symptoms were due to
arsenic rather than to 1-BP in our patients, but cannot do so. As you
know, the source of the arsenic was never determined by NIOSH or anyone
else, and arsenic was only measured in one of the Ichihara/Miller
worker-patients, who had a borderline-elevated level. I hope this is
helpful to you. I'd have called, but am hoping you're not still at your
desk at this hour, considering how the DC-area traffic can be. Cheers,
Larry

-----Original Message-----
From<EMAIL_ADDRESS><EMAIL_ADDRESS>Sent: Wednesday, November 02, 2005 3:16 PM
To: Raymond, Larry
Subject: Costs of treating 1-BP impairment

Larry,
I am doing some research on the costs of treating health problems due to
overexposure to 1-bromopropane.  This will allow me to describe and
monetize the benefits to public health through regulation.

What are the types of treatment that might be carried out on someone
overexposed to 1-BP?  Approximately how much do these different
treatments cost?  Also, how many days of work might someone miss, or how
would their ability to work be affected by overexposure?

I appreciate whatever help you and others can give me in answering these
questions. Margaret Sheppard USEPA/Stratospheric Protection Division
SNAP Program Tel.<PHONE_NUMBER> Fax<PHONE_NUMBER>
email<EMAIL_ADDRESS>


[Federal Register: June 29, 2007 (Volume 72, Number 125)]
[Notices]
[Page 35735-35736]
[DOCID:fr29jn07-90]

=======================================================================
-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-55945; File No. SR-BSE-2007-23]

Self-Regulatory Organizations; Boston Stock Exchange, Inc.;
Notice of Filing and Immediate Effectiveness of Proposed Rule Change
and Amendment No. 1 Thereto Amending Section 5 (Obligations of Market
Makers) of Chapter VI of the Rules of the Boston Options Exchange for
Clarification Purposes Regarding the Guaranteed Directed Order

June 22, 2007.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act''),\1\ and Rule 19b-4 thereunder,\2\ notice is hereby given that
on June 1, 2007, the Boston Stock Exchange, Inc. (``BSE'' or
``Exchange'') filed with the Securities and Exchange Commission
(``Commission'') the proposed rule change as described in Items I and
II below, which Items have been substantially prepared by the Exchange.
BSE has filed the proposal as a non-controversial rule change pursuant
to Section 19(b)(3)(A) of the Act \3\ and Rule 19b-4(f)(6) \4\
thereunder, which renders the proposal effective upon filing with the
Commission. On June 21, 2007, BSE filed Amendment No. 1 to the proposed
rule change. The Commission is publishing this notice to solicit
comments on the proposed rule change, as amended, from interested
persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ 15 U.S.C. 78s(b)(3)(A).
    \4\ 17 CFR 240.19b-4(f)(6).
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Exchange is proposing to amend Section 5 (Obligations of Market
Makers) of Chapter VI of the Rules of the Boston Options Exchange
(``BOX Rules'') for clarification purposes regarding the Guaranteed
Directed Order (``GDO''). The text of the proposed rule is available at
the Exchange, the Commission's Public Reference Room, and on the
Exchange's Web site (http://www.bostonstock.com).

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, BSE included statements
concerning the purpose of, and basis for, the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. The Exchange has prepared summaries, set forth in
Sections A, B, and C below, of the most significant aspects of such
statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    The Exchange is proposing to amend Section 5 (Obligations of Market
Makers) of Chapter VI of the BOX Rules \5\ to clarify that the GDO is
exposed for one time period with an NBBO filter at the end of the
exposition. The section of the BOX Rules which discusses the GDO
contains a cross reference to Chapter V, Section 16(b). The Exchange
proposes to extend the cross reference and numbering to reflect the
specific subsection of the corresponding BOX Rule so that the
Exchange's rules are accurate, comprehendible, and transparent to the
marketplace. The GDO exposure time is not affected by this filing and
remains three seconds, as set forth in Chapter VI, Section 5 of the BOX
Rules.
---------------------------------------------------------------------------

    \5\ Specifically, the Exchange is amending Chapter VI, Section
5(c)(iii)(2)(b)(5) of the BOX Rules. Telephone conversation between
Terri Evans, Special Counsel, Division of Market Regulation,
Commission, and Brian Donnelly, AVP Regulation and Compliance, BSE,
on June 21, 2007 (clarifying the specific rule being amended by the
proposed rule change as described in Amendment No. 1).
---------------------------------------------------------------------------

2. Statutory Basis
    The Exchange believes that the proposal is consistent with the
requirements of Section 6(b) of the Act,\6\ in general, and Section
6(b)(5) of the Act,\7\ in particular, in that it is designed to promote
just and equitable principles of trade, and to protect investors and
the public interest.
---------------------------------------------------------------------------

    \6\ 15 U.S.C. 78f(b).
    \7\ 15 U.S.C. 78f(b)(5).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
impose any burden on competition that is not necessary or appropriate
in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants, or Others

    The Exchange has neither solicited nor received comments on the
proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    Because the foregoing proposed rule change does not (i)
significantly affect the protection of investors or the public
interest; (ii) impose any significant burden on competition; and (iii)
become operative for 30 days after the date of the filing, or such
shorter time as the Commission may designate if consistent with the
protection of investors and the public interest, it has become
effective pursuant to Section 19(b)(3)(A) of the Act \8\ and Rule 19b-
4(f)(6) \9\ thereunder.\10\
---------------------------------------------------------------------------

    \8\ 15 U.S.C. 78s(b)(3)(A).
    \9\ 17 CFR 240.19b-4(f)(6).
    \10\ BSE provided the Commission with written notice of its
intent to file the proposed rule change. See Section 19(b)(3)(A) of
the Act, and Rule 19b-4(f)(6)(iii) thereunder. 15 U.S.C.
78s(b)(3)(A), 17 CFR 240.19b-4(f)(6)(iii).
---------------------------------------------------------------------------

    The Exchange has requested that the Commission waive the 30-day
operative delay. The Commission believes waiving the 30-day operative
delay is consistent with the protection of investors and the public
interest. The Commission notes that the proposed rule change provides
greater specificity as to a cross-reference within a rule, thereby
avoiding confusion resulting from an incomplete cross-reference.
Accordingly, the Commission designates the proposal to be operative
upon filing with the Commission.\11\ At any time within 60 days of the
filing of the proposed rule change, the Commission may summarily
abrogate such rule change if it appears to the Commission that such
action is necessary or appropriate in the public interest, for the
protection of investors, or otherwise in furtherance of the purposes of
the Act.\12\
---------------------------------------------------------------------------

    \11\ For purposes only of waiving the 30-day operative delay of
the proposal, the Commission has considered the proposed rule's
impact on efficiency, competition and capital formation. 15 U.S.C.
78c(f).
    \12\ For purposes of calculating the 60-day period within which
the Commission may summarily abrogate the proposed rule change, as
amended, under Section 19(b)(3)(C) of the Act, the Commission
considers the period to commence on June 21, 2007, the date on which
BSE submitted Amendment No. 1. See 15 U.S.C. 78s(b)(3)(C).
---------------------------------------------------------------------------

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing,

including whether the proposed rule change is consistent with the Act.
Comments may be submitted by any of the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml.
); or     Send an e-mail to<EMAIL_ADDRESS>Please include

File Number SR-BSE-2007-23 on the subject line.

Paper Comments

     Send paper comments in triplicate to Nancy M. Morris,
Secretary, Securities and Exchange Commission, 100 F Street, NE.,
Washington, DC 20549-1090.

All submissions should refer to File Number SR-BSE-2007-23. This file
number should be included on the subject line if e-mail is used. To
help the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's Internet Web site (http://www.sec.gov/rules/sro.shtml
). Copies of the submission, all subsequent amendments, all

written statements with respect to the proposed rule change that are
filed with the Commission, and all written communications relating to
the proposed rule change between the Commission and any person, other
than those that may be withheld from the public in accordance with the
provisions of 5 U.S.C. 552, will be available for inspection and
copying in the Commission's Public Reference Room, 100 F Street, NE.,
Washington, DC 20549, on official business days between the hours of 10
a.m. and 3 p.m. Copies of such filing also will be available for
inspection and copying at the principal office of BSE. All comments
received will be posted without change; the Commission does not edit
personal identifying information from submissions. You should submit
only information that you wish to make available publicly. All
submissions should refer to File Number SR-BSE-2007-23 and should be
submitted on or before July 20, 2007.

    For the Commission, by the Division of Market Regulation,
pursuant to delegated authority.\13\
---------------------------------------------------------------------------

    \13\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Florence E. Harmon,
Deputy Secretary.
 [FR Doc. E7-12604 Filed 6-28-07; 8:45 am]

BILLING CODE 8010-01-P


[Federal Register Volume 86, Number 30 (Wednesday, February 17, 2021)]
[Notices]
[Pages 9932-9934]
[FR Doc No: 2021-03176]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPP-2021-0015; FRL-10019-59]

Notice of Receipt of Requests To Voluntarily Cancel Certain
Pesticide Registrations

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Federal Insecticide, Fungicide, and
Rodenticide Act (FIFRA), EPA is issuing a notice of receipt of requests
by registrants to voluntarily cancel certain pesticide registrations.
EPA intends to grant these requests at the close of the comment period
for this announcement unless the Agency receives substantive comments
within the comment period that would merit its further review of the
requests, or unless the registrants withdraw its requests. If these
requests are granted, any sale, distribution, or use of products listed
in this notice will be permitted after the registrations have been
cancelled only if such sale, distribution, or use is consistent with
the terms as described in the final order.

DATES: Comments must be received on or before August 16, 2021.

ADDRESSES: Submit your comments, identified by docket identification
(ID) number EPA-HQ-OPP-2021-0015, by one of the following methods:
    Federal eRulemaking Portal: http://www.regulations.gov. Follow the
online instructions for submitting comments. Do not submit
electronically any information you consider to be Confidential Business
Information (CBI) or other information whose disclosure is restricted
by statute.
    Mail: OPP Docket, Environmental Protection Agency Docket Center
(EPA/DC), (28221T), 1200 Pennsylvania Ave. NW, Washington, DC 20460-
0001.
    Submit written withdrawal request by mail to: Christopher Green,
Registration Division (7502P), Office of Pesticide Programs,
Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington,
DC 20460-0001.
    Hand Delivery: To make special arrangements for hand delivery or
delivery of boxed information, please follow the instructions at http://www.epa.gov/dockets/contacts.html.
    Due to the public health concerns related to COVID-19, the EPA
Docket Center (EPA/DC) and Reading Room is closed to visitors with
limited exceptions. The staff continues to provide remote customer
service via email, phone, and webform. For the latest status
information on EPA/DC services and docket access, visit https://www.epa.gov/dockets.

FOR FURTHER INFORMATION CONTACT: Christopher Green, Registration
Division (7502P), Office of Pesticide Programs, Environmental
Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460-
0001; telephone number:<PHONE_NUMBER>; email address:
<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this action apply to me?

    This action is directed to the public in general, and may be of
interest to a wide range of stakeholders including environmental, human
health, and agricultural advocates; the chemical industry; pesticide
users; and members of the public interested in the sale, distribution,
or use of pesticides.

B. What should I consider as I prepare my comments for EPA?

    1. Submitting CBI. Do not submit this information to EPA through

regulations.gov or email. Clearly mark the part or all of the
information that you claim to be CBI. For CBI information in a disk or
CD-ROM that you mail to EPA, mark the outside of the disk or CD-ROM as
CBI and then identify electronically within the disk or CD-ROM the
specific information that is claimed as CBI. In addition to one
complete version of the comment that includes information claimed as
CBI, a copy of the comment that does not contain the information
claimed as CBI must be submitted for inclusion in the public docket.
Information so marked will not be disclosed except in accordance with
procedures set forth in 40 CFR part 2.
    2. Tips for preparing your comments. When preparing and submitting
your comments, see the commenting tips at http://www.epa.gov/dockets/comments.html.

II. What action is the Agency taking?

    This notice announces receipt by EPA of requests from registrants
to cancel certain pesticide products registered under FIFRA section 3
(7 U.S.C. 136a) or 24(c) (7 U.S.C. 136v(c)). The affected products and
the registrants making the requests are identified in Tables 1-2 of
this unit.
    Unless a request is withdrawn by the registrant or if the Agency
determines that there are substantive comments that warrant further
review of this request, EPA intends to issue an order in the Federal
Register canceling the affected registrations.

                      Table 1--Product Registrations With Pending Requests for Cancellation
----------------------------------------------------------------------------------------------------------------
                                         Company
           Registration No.                No.              Product name                 Active ingredients
----------------------------------------------------------------------------------------------------------------
241-74................................        241  Cycocel Plant Growth Regulant.  Chlormequat chloride.
69969-1...............................      69969  Flight Control................  Anthraquinone.
69969-4...............................      69969  AV-1011 Rice Seed Treatment...  Anthraquinone.
----------------------------------------------------------------------------------------------------------------

    Table 2 of this unit includes the names and addresses of record for
all registrants of the products in Table1 of this unit, in sequence by
EPA company number. This number corresponds to the first part of the
EPA registration numbers of the products listed in Table 1 of this
unit.

         Table 2--Registrants Requesting Voluntary Cancellation
------------------------------------------------------------------------
     EPA  company  No.                 Company name and address
------------------------------------------------------------------------
241........................  BASF Corporation, 26 Davis Drive, P.O. Box
                              13528, Research Triangle Park, NC 27709-
                              3528.
69969......................  Arkion Life Sciences, LLC, Airepel
                              Division, Agent Name: Landis
                              International, Inc., 3815 Madison Highway,
                              P.O. Box 5126, Valdosta, GA 31603-5126.
------------------------------------------------------------------------

III. What is the Agency's authority for taking this action?

    Section 6(f)(1) of FIFRA (7 U.S.C. 136d(f)(1)) provides that a
registrant of a pesticide product may at any time request that any of
its pesticide registrations be canceled or amended to terminate one or
more uses. FIFRA further provides that, before acting on the request,
EPA must publish a notice of receipt of any such request in the Federal
Register.
    Section 6(f)(1)(B) of FIFRA (7 U.S.C. 136d(f)(1)(B)) requires that
before acting on a request for voluntary cancellation, EPA must provide
a 30-day public comment period on the request for voluntary
cancellation or use termination. In addition, FIFRA section 6(f)(1)(C)
(7 U.S.C. 136d(f)(1)(C)) requires that EPA provide a 180-day comment
period on a request for voluntary cancellation or termination of any
minor agricultural use before granting the request, unless:
    1. The registrants request a waiver of the comment period, or
    2. The EPA Administrator determines that continued use of the
pesticide would pose an unreasonable adverse effect on the environment.
    The registrants listed in Table 2 of Unit II have not requested
that EPA waive the 180-day comment period. Accordingly, EPA will
provide a 180-day comment period on the proposed requests.

IV. Procedures for Withdrawal of Request

    Registrants who choose to withdraw a request for product
cancellation should submit the withdrawal in writing to the person
listed under FOR FURTHER INFORMATION CONTACT. If the products have been
subject to a previous cancellation action, the effective date of
cancellation and all other provisions of any earlier cancellation
action are controlling.

V. Provisions for Disposition of Existing Stocks

    Existing stocks are those stocks of registered pesticide products
that are currently in the United States and that were packaged,
labeled, and released for shipment prior to the effective date of the
cancellation action.
    In any order issued in response to these requests for cancellation
of product registrations EPA proposes to include the following
provisions for the treatment of any existing stocks of the products
listed in Table 1 of Unit II.
    For all voluntary product cancellations, listed in Table 1 of Unit
II, the registrants will be permitted to sell and distribute existing
stocks of voluntarily canceled products for 1 year after the effective
date of the cancellation, which will be the date of publication of the
cancellation order in the Federal Register. Thereafter, registrants
will be prohibited from selling or distributing the products identified
in Table 1 of Unit II, except for export consistent with FIFRA section
17 (7 U.S.C. 136o) or for proper disposal.
    Persons other than the registrant may sell, distribute, or use
existing stocks of the canceled products until supplies are exhausted,
provided that such sale, distribution, or use is consistent with the
terms of the previously approved labeling on, or that accompanied, the
canceled products.

    Authority: 7 U.S.C. 136 et seq.

    Dated: February 4, 2021.
Marietta Echeverria,
Acting Director, Registration Division, Office of Pesticide Programs.
[FR Doc. 2021-03176 Filed 2-16-21; 8:45 am]
BILLING CODE 6560-50-P